BRIEF published on 01/13/2025 at 11:31, 1 year ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
PRESS RELEASE published on 01/13/2025 at 11:26, 1 year ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 1 year 1 month ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
BRIEF published on 12/24/2024 at 20:51, 1 year 1 month ago GenSight Biologics obtient un financement de 1,5 million d'euros auprès d'investisseurs existants Financement Investisseurs Thérapie Génique Mandats GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 1 month ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 1 month ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 1,5 million d'euros auprès d'investisseurs existants pour le développement de thérapies géniques innovantes. Perspectives de croissance et objectifs à court terme Croissance Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 11/13/2024 at 07:35, 1 year 2 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
BRIEF published on 11/13/2024 at 07:35, 1 year 2 months ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 2 months ago Informations privilégiées / Autres communiqués GenSight Biologics soumet le dossier de LUMEVOQ® à l'ANSM pour reprendre le programme d'accès compassionnel en France. Premieres injections prévues en décembre 2024 Thérapie Génique GenSight Biologics LUMEVOQ ANSM Neuropathie Optique
Published on 02/06/2026 at 03:50, 1 hour 14 minutes ago High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 02:45, 2 hours 19 minutes ago High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 00:57, 4 hours 7 minutes ago Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 5 hours 4 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 5 hours 49 minutes ago Amarc Further Expands Its Toodoggone Technical Team
Published on 02/05/2026 at 19:27, 9 hours 36 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 10 hours 17 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 10 hours 54 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 11 hours 8 minutes ago Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 11 hours 24 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 19:15, 9 hours 49 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 9 hours 49 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 9 hours 49 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
